$AMIX
Autonomix Medical, Inc.

2024 Q1 Form 10-Q Financial Statement

#000168316824000918 Filed on February 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.575M $2.323M $1.352M
YoY Change 365.63% 107.89%
% of Gross Profit
Research & Development $841.0K $601.0K $782.6K
YoY Change 163.45% 202.01% 466.29%
% of Gross Profit
Depreciation & Amortization $46.00K $35.00K
YoY Change
% of Gross Profit
Operating Expenses $2.416M $2.924M $6.690M
YoY Change 267.46% 437.5% 748.57%
Operating Profit -$2.924M -$5.820M
YoY Change 437.5%
Interest Expense $34.00K $33.00K $24.55K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$3.026M -$189.0K -$239.5K
YoY Change
Pretax Income -$5.408M -$3.113M -$6.905M
YoY Change 722.53% 472.24% 775.83%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.408M -$3.113M -$6.040M
YoY Change 722.53% 472.24% 1248.21%
Net Earnings / Revenue
Basic Earnings Per Share -$0.23 -$8.78
Diluted Earnings Per Share -$0.29 -$0.23 -$0.33
COMMON SHARES
Basic Shares Outstanding 18.79M shares 13.80M shares 687.8K
Diluted Shares Outstanding 13.80M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.608M $1.218M $2.145M
YoY Change
Cash & Equivalents $8.608M $1.218M $2.145M
Short-Term Investments
Other Short-Term Assets $783.0K $467.0K $62.30K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.391M $1.685M $2.208M
YoY Change 985.66%
LONG-TERM ASSETS
Property, Plant & Equipment $16.00K $14.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $110.0K $162.7K
YoY Change
Total Long-Term Assets $16.00K $124.0K $162.6K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $9.391M $1.685M $2.208M
Total Long-Term Assets $16.00K $124.0K $162.6K
Total Assets $9.407M $1.809M $2.370M
YoY Change 987.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $492.0K $663.0K $402.9K
YoY Change 184.39%
Accrued Expenses $285.0K $310.0K $34.60K
YoY Change 493.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $777.0K $973.0K $437.5K
YoY Change 251.58%
LONG-TERM LIABILITIES
Long-Term Debt $1.002M $1.457M $61.70K
YoY Change
Other Long-Term Liabilities $4.974M $4.795M
YoY Change
Total Long-Term Liabilities $1.002M $6.431M $4.857M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $777.0K $973.0K $437.5K
Total Long-Term Liabilities $1.002M $6.431M $4.857M
Total Liabilities $1.779M $7.404M $5.295M
YoY Change 704.98%
SHAREHOLDERS EQUITY
Retained Earnings -$39.00M -$33.56M
YoY Change 65.65%
Common Stock $19.00K $14.00K
YoY Change 58.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.628M -$5.595M -$2.924M
YoY Change
Total Liabilities & Shareholders Equity $9.407M $1.809M $2.370M
YoY Change 987.51%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$5.408M -$3.113M -$6.040M
YoY Change 722.53% 472.24% 1248.21%
Depreciation, Depletion And Amortization $46.00K $35.00K
YoY Change
Cash From Operating Activities -$2.287M -$2.557M -$1.804M
YoY Change 93.03% 169.46%
INVESTING ACTIVITIES
Capital Expenditures $3.000K $16.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.000K -$16.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.680M 1.645M 3.085M
YoY Change 1334.07%
NET CHANGE
Cash From Operating Activities -2.287M -2.557M -1.804M
Cash From Investing Activities -3.000K -16.00K
Cash From Financing Activities 9.680M 1.645M 3.085M
Net Change In Cash 7.390M -927.7K 1.281M
YoY Change -1549.59% -291.26%
FREE CASH FLOW
Cash From Operating Activities -$2.287M -$2.557M -$1.804M
Capital Expenditures $3.000K $16.00K
Free Cash Flow -$2.290M -$2.573M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001617867
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Net Income Loss
NetIncomeLoss
-10018000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1333000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4361000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1234000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33561000 usd
AMIX Warrant Expense Termination Agreement
WarrantExpenseTerminationAgreement
4556000 usd
AMIX Warrant Liability Markto Market
WarrantLiabilityMarktoMarket
418000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41940
dei Entity Registrant Name
EntityRegistrantName
Autonomix Medical, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1607810
dei Entity Address Address Line1
EntityAddressAddressLine1
21 Waterway Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
The Woodlands
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77380
dei City Area Code
CityAreaCode
(713)
dei Local Phone Number
LocalPhoneNumber
588-6150
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
AMIX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18793974 shares
CY2023Q4 us-gaap Cash
Cash
1218000 usd
CY2023Q1 us-gaap Cash
Cash
865000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
467000 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
0 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1685000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
865000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
110000 usd
CY2023Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
124000 usd
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
0 usd
CY2023Q4 us-gaap Assets
Assets
1809000 usd
CY2023Q1 us-gaap Assets
Assets
865000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
663000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
173000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
310000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
48000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
973000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
221000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4974000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
1457000 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
0 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6431000 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0 usd
CY2023Q4 us-gaap Liabilities
Liabilities
7404000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
221000 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7100000 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14430221 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14430221 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12336571 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12336571 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
14000 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
12000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27952000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24175000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33561000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23543000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5595000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
644000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1809000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
865000 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2323000 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
345000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3674000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
995000 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
601000 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
199000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1384000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
338000 usd
CY2023Q4 AMIX Warrant Expense Termination Agreement
WarrantExpenseTerminationAgreement
0 usd
CY2022Q4 AMIX Warrant Expense Termination Agreement
WarrantExpenseTerminationAgreement
0 usd
AMIX Warrant Expense Termination Agreement
WarrantExpenseTerminationAgreement
4556000 usd
AMIX Warrant Expense Termination Agreement
WarrantExpenseTerminationAgreement
0 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
2924000 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
544000 usd
us-gaap Operating Expenses
OperatingExpenses
9614000 usd
us-gaap Operating Expenses
OperatingExpenses
1333000 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2924000 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-544000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9614000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1333000 usd
CY2023Q4 AMIX Warrant Liability Markto Market
WarrantLiabilityMarktoMarket
179000 usd
CY2022Q4 AMIX Warrant Liability Markto Market
WarrantLiabilityMarktoMarket
-0 usd
AMIX Warrant Liability Markto Market
WarrantLiabilityMarktoMarket
418000 usd
AMIX Warrant Liability Markto Market
WarrantLiabilityMarktoMarket
-0 usd
CY2023Q4 us-gaap Interest Expense
InterestExpense
33000 usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
-0 usd
us-gaap Interest Expense
InterestExpense
33000 usd
us-gaap Interest Expense
InterestExpense
-0 usd
CY2023Q4 us-gaap Interest And Other Income
InterestAndOtherIncome
23000 usd
CY2022Q4 us-gaap Interest And Other Income
InterestAndOtherIncome
0 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
47000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
0 usd
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-189000 usd
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-404000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 usd
CY2023Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3113000 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-544000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10018000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1333000 usd
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-3113000 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-544000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10018000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1333000 usd
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13799170 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13799170 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11999071 shares
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11999071 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13487444 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13487444 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11999071 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11999071 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1959000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-341000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1618000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-448000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1170000 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-544000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
626000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
644000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-865000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2840000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2619000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6040000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
151000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
346000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2924000 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-3113000 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
212000 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
230000 usd
CY2023Q4 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5595000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10018000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1333000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
363000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
35000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0 usd
AMIX Warrant Expense Termination Agreement
WarrantExpenseTerminationAgreement
4556000 usd
AMIX Warrant Expense Termination Agreement
WarrantExpenseTerminationAgreement
0 usd
AMIX Warrant Liability Markto Market
WarrantLiabilityMarktoMarket
418000 usd
AMIX Warrant Liability Markto Market
WarrantLiabilityMarktoMarket
0 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
467000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-9000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
490000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
92000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
262000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4361000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1234000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2840000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2000000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
110000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
-0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4730000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
353000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1234000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
865000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2044000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1218000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
810000 usd
AMIX Warrants Issued For Debt Issuance Costs
WarrantsIssuedForDebtIssuanceCosts
576000 usd
AMIX Warrants Issued For Debt Issuance Costs
WarrantsIssuedForDebtIssuanceCosts
0 usd
AMIX Proceeds From Cashless Exercise Of Warrants
ProceedsFromCashlessExerciseOfWarrants
1000 usd
AMIX Proceeds From Cashless Exercise Of Warrants
ProceedsFromCashlessExerciseOfWarrants
0 usd
CY2023Q4 AMIX Working Capital
WorkingCapital
700000 usd
CY2022Q4 us-gaap Cash
Cash
1200000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_zFoEqjuhIVLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Use of Estimates in Financial Statement Presentation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity related instruments, initial and recurring fair value measurements for the warrant liability and the valuation allowance related to deferred taxes. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10718529 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6569929 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1703600 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.26
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
AMIX Share Based Compensation Arrangement By Share Based Payment Award Options Exchanged In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedInPeriod
0 shares
AMIX Share Based Compensation Arrangements By Share Based Payment Award Options Exchanged In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1703600 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.26
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y5M19D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
157117 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.00
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P9Y3M
CY2023Q4 AMIX Fair Value Of Options Granted
FairValueOfOptionsGranted
3 usd
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2700000 usd
us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
100000 usd
us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
100000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
100000 usd
CY2023Q1 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
100000 usd

Files In Submission

Name View Source Status
0001683168-24-000918-index-headers.html Edgar Link pending
0001683168-24-000918-index.html Edgar Link pending
0001683168-24-000918.txt Edgar Link pending
0001683168-24-000918-xbrl.zip Edgar Link pending
amix-20231231.xsd Edgar Link pending
autonomix_ex3101.htm Edgar Link pending
autonomix_ex3102.htm Edgar Link pending
autonomix_ex3201.htm Edgar Link pending
autonomix_ex3202.htm Edgar Link pending
autonomix_i10q-123123.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
autonomix_i10q-123123_htm.xml Edgar Link completed
amix-20231231_def.xml Edgar Link unprocessable
amix-20231231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
amix-20231231_cal.xml Edgar Link unprocessable
amix-20231231_pre.xml Edgar Link unprocessable